Key result
HELP apheresis provides a valuable therapeutic option for managing acute atherothrombotic disorders.
Why the study?
Conventional treatments for atherothrombotic disorders have known limitations, while HELP apheresis shows compelling biochemical evidence and long-term safety warranting further research.
Does HELP apheresis improve outcomes in patients with atherothrombotic disorders?
Does HELP apheresis improve outcomes in patients with atherothrombotic disorders?
HELP apheresis represents a potential therapeutic tool for various atherothrombotic and microcirculatory disorders, including MI, stroke, and post-CABG.
May support adjunctive use in refractory cases; leaves open need for randomized confirmation before practice change.
Given the importance of atherothrombotic disorders for the public health system, and the known limitations of conventional treatment on one hand and the compelling biochemical evidence and long-term safety of HELP (Heparin-mediated Extracorporeal LDL/Fibrinogen Precipitation) apheresis on the other hand, this approach provides a most valuable tool for further medical research and treatment of the various atherothrombotic and microcirculatory disorders. The present contribution reviews the recent developments in chronic and single application of apheresis in cardiology with particular emphasis on the newly discovered therapeutic possibilities for myocardial infarction, stroke, and after coronary artery bypass grafting.
No takes yet. Share an insight, caveat, or question.
Beate Roxane Jaeger (2003) conducted a review in Atherothrombotic and microcirculatory disorders. HELP (Heparin-mediated Extracorporeal LDL/Fibrinogen Precipitation) apheresis was evaluated. HELP (Heparin-mediated Extracorporeal LDL/Fibrinogen Precipitation) apheresis provides a valuable tool for the treatment of atherothrombotic disorders, including myocardial infarction and stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: